Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II studyReportar como inadecuado




Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 14:737

Clinical oncology

Abstract

BackgroundDose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer mCRC.

Methods49 patients with previously untreated mCRC were recruited. Nineteen received capecitabine 1750 mg-m oral BD days 1–7oxaliplatin 85 mg-mi.v. day 1 and bevacizumab 5 mg-kg i.v. day 1 using a 14-day cycle C1750. Following toxicity concerns capecitabine was reduced to 1500 mg-moral BD C1500 and 30 further patients recruited.

ResultsOver 80% of patients received at least 75% of planned chemotherapy doses over the first two cycles. At C1750 Grade 3 or higher toxicity occurred in 74% 95% CI 49% to 91% and on C1500 in 70% 95% CI 51% to 85%. The median progression-free survival was 6.9 months 95% CI 4.7 to 8.7 for C1750 dose and 8.9 months 95% CI 4.1 to 12.4 for C1500. 3 treatment-related deaths occurred.

ConclusionsDose intense capecitabine and oxaliplatin with bevacizumab does not show additional efficacy and has potentially significant toxicity. Its use outside of clinical trials is not recommended.

Trial registrationISRCTN41540878

Keywords6 in alphabetical order bevacizumab Capecitabine Dose-intense Colorectal cancer Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-14-737 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Christopher GCA Jackson - Katrina Sharples - Paul I Thompson - Anne O’Donnell - Bridget Anne Robinson - David J Perez

Fuente: https://link.springer.com/







Documentos relacionados